J
14.83
0.27 (1.85%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Jade Biosciences, Inc. | 混合的 | - |
AIStockmoo 评分
-0.5
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -1.5 |
| 平均 | -0.50 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.04% |
| 机构持股比例 | 33.40% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Fairmount Funds Management Llc | 31 Dec 2025 | 4,553,494 |
| Remedium Capital Partners, Llc | 31 Dec 2025 | 1,577,750 |
| Versant Venture Management, Llc | 31 Dec 2025 | 1,525,820 |
| Avidity Partners Management Lp | 31 Dec 2025 | 1,400,708 |
| 52周波幅 | ||
| 中 | 25.00 (68.58%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Jan 2026 | 25.00 (68.58%) | 购买 | 13.19 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合